홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
Heatmap
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
LIXT
#4482
Lixte Biotechnology Holdings, Inc. Common Stock
3.0
5
USD
+4.81%
부문:
헬스케어
베이스:
USD
수익 통화:
USD
일일 변동 비율
년간 변동
일일 변동
+4.81%
월간 변동
-1.61%
6달 변화
-29.40%
년간 변동율
+138.28%
이전 종가
2.9
1
Open
3.0
2
Bid
Ask
Low
3.0
0
High
3.0
5
양
11
마켓
주식
헬스케어
LIXT
Open full chart
Financials
Overview
성명
Statistics
Quarterly
Annual
Value
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
2.68 M
2.68 M
4.56 M
5.7 M
11.62 M
—
Valuation ratios
Enterprise value
7.91 M
5.36 M
3.24 M
28.36 M
43.58 M
80.54 M
Price to earnings ratio
-1.28
-0.83
-0.7
-4.26
-3.12
-8.92
Price to sales ratio
—
—
—
—
—
—
Price to cash flow ratio
-1.44
-0.94
-0.82
-6.09
-6.2
-14.05
Price to book ratio
-1.71
-0.33
-0.32
-3.32
2.4
-1.58
EBITDA 비율에 대한 기업 가치
—
—
—
—
—
—
Profitability ratios
Return on assets %
-0.54
-0.47
-0.65
-0.36
-0.21
-1.69
Return on equity %
-0.75
-0.61
-1.19
-0.4
-0.24
-2.44
Return on invested capital %
—
—
—
—
-325.76
—
Gross margin %
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
3.6
4.26
1.84
10.42
3.88
20.41
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0
0
0
0
0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
-0.27
-0.23
-0.18
-0.15
-0.22
-0.78
EBIT per share
-0.27
-0.29
-0.28
-0.29
-0.38
-1.24
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
0.46
0.56
0.33
0.47
1.05
2.41
Net current asset value per share
0.51
0.61
0.36
0.88
1.07
2.93
Tangible book value per share
-1.19
-0.95
0.24
0.38
1.64
1.31
Working capital per share
0.37
0.47
0.17
0.8
0.79
2.23
Book value per share
-1.19
-0.95
0.24
0.38
1.64
1.31
뉴스
LIXTE Biotechnology appoints Sidney Braun to lead Liora subsidiary
LIXTE expands clinical trial for ovarian cancer treatment
스파르탄 캐피털, Lixte의 430만 달러 규모 유상증자 주선
Lixte Biotechnology stock falls after $4.3 million direct offering
Spartan Capital acts as placement agent in Lixte’s $4.3 million offering
릭스테 바이오, 430만 달러 규모 직접 공모 후 주가 하락
Lixte Biotechnology stock falls after $4.3 million direct offering
Lixte Biotechnology raises $4.3 million in registered direct offering
Lixte Biotechnology, 주주총회서 이사 선임 및 주식 계획 수정안 승인
Lixte Biotechnology shareholders approve board nominees and stock plan amendment
Lixte Biotechnology, 영국 Liora 인수 후 주가 하락
Lixte Biotechnology stock falls after acquiring UK-based Liora